Microscopic polyangiitis epidemiology and demographics
Microscopic polyangiitis Microchapters |
Differentiating Microscopic polyangiitis from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Microscopic polyangiitis epidemiology and demographics On the Web |
American Roentgen Ray Society Images of Microscopic polyangiitis epidemiology and demographics |
FDA on Microscopic polyangiitis epidemiology and demographics |
CDC on Microscopic polyangiitis epidemiology and demographics |
Microscopic polyangiitis epidemiology and demographics in the news |
Blogs on Microscopic polyangiitis epidemiology and demographics |
Risk calculators and risk factors for Microscopic polyangiitis epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Ali Poyan Mehr, M.D. [2]Associate Editor(s)-in-Chief: Vamsikrishna Gunnam M.B.B.S [3]
Overview
The prevalence of Microscopic polyangiitis higher in Southern European countries and Asia.The incidence of GPA was similar to that of MPA.MPO‐ANCAs when positive in a patient was a marker of poor prognosis in the population of patients with AAV.
Epidemiology
Incidence
- The incidence of Microscopic polyangiitis is approximately 3.3 per 100,000 individuals worldwide.[1]
- Microscopic polyangiitis in Europe is seen with higher incidences in Southern countries than in Northern countries. [2]
- The incidence of Microscopic polyangiitis is estimated to be 0.59 per 100,000 individuals per year in the United Kingdom.[3]
- During the last two decades, the incidences of Microscopic polyangiitis has increased, which may be due to increased testing for various vasculitis as a result of availability of testing for ANCA.
Prevalence
- The prevalence of Microscopic polyangiitis is approximately 42.1 per 100,000 individuals worldwide.[4]
Age
- The incidence of Microscopic polyangiitis increases with age; the median age at diagnosis is 60 years.[5]
Gender
- Males are more commonly affected with Microscopic polyangiitis than females (1.8:1).[5]
Race
- Microscopic polyangiitis tends to affect individuals of Asian and Southern European descent.[6]
References
- ↑ Berti A, Cornec D, Crowson CS, Specks U, Matteson EL (December 2017). "The Epidemiology of Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis in Olmsted County, Minnesota: A Twenty-Year US Population-Based Study". Arthritis Rheumatol. 69 (12): 2338–2350. doi:10.1002/art.40313. PMID 28881446.
- ↑ Chung SA, Seo P (2010). "Microscopic polyangiitis". Rheum Dis Clin North Am. 36 (3): 545–58. doi:10.1016/j.rdc.2010.04.003. PMC 2917831. PMID 20688249.
- ↑ Watts RA, Mooney J, Skinner J, Scott DG, Macgregor AJ (2012). "The contrasting epidemiology of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis". Rheumatology (Oxford). 51 (5): 926–31. doi:10.1093/rheumatology/ker454. PMC 3465699. PMID 22258386.
- ↑ Berti A, Cornec D, Crowson CS, Specks U, Matteson EL (December 2017). "The Epidemiology of Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis in Olmsted County, Minnesota: A Twenty-Year US Population-Based Study". Arthritis Rheumatol. 69 (12): 2338–2350. doi:10.1002/art.40313. PMID 28881446.
- ↑ 5.0 5.1 Mohammad, A. J.; Jacobsson, L. T. H.; Mahr, A. D.; Sturfelt, G.; Segelmark, M. (2007). "Prevalence of Wegener's granulomatosis, microscopic polyangiitis, polyarteritis nodosa and Churg Strauss syndrome within a defined population in southern Sweden". Rheumatology. 46 (8): 1329–1337. doi:10.1093/rheumatology/kem107. ISSN 1462-0324.
- ↑ Fujimoto S, Watts RA, Kobayashi S, Suzuki K, Jayne DR, Scott DG, Hashimoto H, Nunoi H (October 2011). "Comparison of the epidemiology of anti-neutrophil cytoplasmic antibody-associated vasculitis between Japan and the U.K". Rheumatology (Oxford). 50 (10): 1916–20. doi:10.1093/rheumatology/ker205. PMID 21798892.